Note 18. Contingent liabilities and licence agreement The consolidated entity has entered into a licence agreement whereby it is obliged to make royalty payments on future sales and make future cash milestone payments if certain events occur. This agreement includes the following: • milestone payment based on the initiation of the first Phase III clinical trial for each product; • milestone payments based on first grant of a marketing authorisation for each product; and • royalty payments based on net sales. The licence agreement was extended for an additional twelve months during the year ended 30 June 2025. Note 19. Related party transactions Parent entity Noxopharm Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 21. Key management personnel Disclosures relating to key management personnel are set out in note 16 and the remuneration report included in the directors’ report. Transactions with related parties There were no transactions with related parties during the reporting period. Receivable from and payable to related parties As a 30 June 2025 there is a trade receivable of $45,000 owing from Audio Pixels Holdings Limited (a company which Fred Bart is the Chairman), for consulting services provided by Shawn van Boheemen. Note 20. Parent entity information Set out below is the supplementary information about the parent entity in accordance with the Corporations Act 2001. Statement of profit or loss and other comprehensive income Parent 2024 2024 $ $ Loss after income tax (3,052,933) (2,486,556) Total comprehensive income (3,052,933) (2,486,556) Annual Report 2025 40
RkJQdWJsaXNoZXIy MjE2NDg3